Cusick Matthew F, Libbey Jane E, Oh Luke, Jordan Shaun, Fujinami Robert S
Department of Pathology, University of Utah , Salt Lake City, UT , USA and.
Autoimmunity. 2015 Jun;48(4):222-30. doi: 10.3109/08916934.2014.984836. Epub 2014 Nov 20.
Acthar gel is indicated for the treatment of acute exacerbations of multiple sclerosis (MS) in adults. Its effects on immune cells during a relapse are unknown. This study investigated the effects of Acthar in an animal model of relapsing-remitting MS, using SJL/J mice sensitized with myelin peptide. All animal studies were reviewed and approved by the University of Utah Institutional Animal Care and Use Committee and conducted in accordance with the guidelines prepared by the Committee on Care and Use of Laboratory Animals, Institute of Laboratory Animals Resources, National Research Council. Mice injected with Acthar to treat the second attack had a significantly lower mean clinical score during relapse and a significantly reduced cumulative disease burden compared to Placebo gel-treated mice. Furthermore, Acthar treatment ameliorated inflammation/demyelination in the spinal cord and markedly suppressed ex vivo myelin peptide-induced CD4(+) T cell proliferation.
促肾上腺皮质激素凝胶适用于治疗成人多发性硬化症（MS）的急性加重期。其在复发期间对免疫细胞的作用尚不清楚。本研究使用用髓磷脂肽致敏的SJL/J小鼠，在复发缓解型MS动物模型中研究了促肾上腺皮质激素的作用。所有动物研究均经过犹他大学机构动物护理和使用委员会的审查和批准，并按照美国国家研究委员会实验动物资源研究所实验动物护理和使用委员会制定的指南进行。与接受安慰剂凝胶治疗的小鼠相比，注射促肾上腺皮质激素治疗第二次发作的小鼠在复发期间的平均临床评分显著降低，累积疾病负担显著减轻。此外，促肾上腺皮质激素治疗改善了脊髓中的炎症/脱髓鞘，并显著抑制了体外髓磷脂肽诱导的CD4(+) T细胞增殖。
